gas ...I have to thank you for the heads up a couple of months ago. You warned that KERX was going lower stock price was about $10 at the time.
I reviewed my portfolio and lightened up reducing KERX by 50% and saved capital .
GlaxoSmithKline (GSK) will partner with Idera Pharmaceuticals to research, develop and commercialize selected molecules from Idera’s third-generation antisense platform against targets in renal disease.
The deal, announced today by Idera, could generate up to $100 million-plus for Idera, starting with the $2.5 million that GSK agreed to pay upfront under the companies’ exclusive worldwide collaboration and license agreement.
Idera has two drug discovery platforms based on novel nucleic acid therapeutics: Gene silencing oligonucleotides (GSOs), and toll-like receptor (TLR) antagonists implicated in conditions that include autoimmune diseases and forms of lymphoma.
Idera says it is using its GSO platform to pursue third-generation antisense drug candidates for a variety of genetically derived disorders.
“Based on its validation in preclinical models, we believe our GSO technology has the potential to overcome the remaining hurdles of current antisense technologies, including efficient delivery without a carrier, reduced immunotoxicity, and increased potency,” Idera states on its website.
Idera added that it is continuing to conduct preclinical studies, with the goal of advancing GSO drug candidates into clinical development. The company said it is evaluating opportunities to clinically demonstrate its GSOs in established disease targets as well as identifying new targets for development and commercialization.
GSK agreed to pay Idera approximately $100 million in payments tied to development and regulatory milestones. Idera is also eligible to receive royalties on all sales upon commercialization at varying rates up to five percent on annual net sales above $500 million.
“This collaboration broadens the utility of our third generation antisense platform beyond the stated areas of focus for Idera in cancers and rare diseases,” Clayton Fletcher, Idera svp of business development and strategic initiatives, said in a statement.
Added John Lepore, GSK svp and head of its Metabolic Pathways and Cardiovascular Therapy Area Unit: “Idera’s antisense platform offers a new path to explore whether gene silencing technology can help stop or slow chronic kidney disease.”
Sentiment: Strong Buy
KERX,IDRA &TROV for me.... looking at CRIS again.
no news ....they run this up periodically . That said, could pop big tomorrow as it runs consistently for about 3 days and then take profits. I don't know ,but maybe for about the same money you should look at IDRA .
Popped this morning on news ...and has actual catalysts coming up....
Shares of Idera Pharmaceuticals jumped today on a new partnership with London drug giant GlaxoSmithKline potentially worth $100 million in milestone payments plus royalties on drugs for kidney diseases.
Cambridge-based Idera (Nasdaq: IDRA) will get $2.5 million up front in the deal, adding to the $95 million it reported as of Sept. 30. But in addition to the $100 million in regulatory and development milestone payments, the small Cambridge biotech stands to get royalties from GSK (NYSE: GSK) of up to 5 percent on future royalties, which the company estimates as “in excess of $500 million.”
currently $3.52 up 10% today
You are really an Idiot.,you imbecile. .
....Not to mention the fact that you are bi-polar lunatic to boot.